A randomized, double-blind, biomarker-selected, phase II clinical trial of maintenance poly ADP-ribose polymerase inhibition with rucaparib following chemotherapy for metastatic urothelial carcinoma
Name:
35960902.pdf
Size:
538.4Kb
Format:
PDF
Description:
Identified with Open Access button
Authors
Crabb, S. J.Hussain, S.
Soulis, E.
Hinsley, S.
Dempsey, L.
Trevethan, A.
Song, Yee Pei
Barber, J.
Frew, J.
Gale, J.
Faust, G.
Brock, S.
McGovern, U.
Parikh, O.
Enting, D.
Sundar, S.
Ratnayake, G.
Lees, K.
Birtle, A. J.
Powles, T.
Jones, R. J.
Affiliation
Southampton Experimental Cancer Medicine Centre, University of Southampton, Southampton, United KingdomIssue Date
2022
Metadata
Show full item recordAbstract
Purpose: A DNA repair deficiency (DRD) phenotype exists within a subset of metastatic urothelial carcinomas (mUC) predicting benefit from platinum-based chemotherapy. We tested switch maintenance therapy with the poly ADP-ribose polymerase inhibitor rucaparib, following chemotherapy, for DRD biomarker-positive mUC. Methods: DRD biomarker-positive mUC patients, within 10 weeks of chemotherapy, and without cancer progression, were randomly assigned (1:1) to maintenance rucaparib 600 mg twice a day orally, or placebo, until disease progression. The primary end point was progression-free survival (PFS). Statistical analysis targeted a hazard ratio of 0.5 with a 20% one-sided α for this signal-seeking trial. PFS (RECIST 1.1) was compared between trial arms, by intention to treat, within a Cox model. Results: Out of 248 patients, 74 (29.8%) were DRD biomarker-positive and 40 were randomly assigned. A total of 12 (60%) and 20 (100%) PFS events occurred in the rucaparib and placebo arms, respectively (median follow-up was 94.6 weeks in those still alive). Median PFS was 35.3 weeks (80% CI, 11.7 to 35.6) with rucaparib and 15.1 weeks (80% CI, 11.9 to 22.6) with placebo (hazard ratio, 0.53; 80% CI, 0.30 to 0.92; one-sided P = .07). In the safety population (n = 39) treatment-related adverse events were mostly low grade. Patients received a median duration of 10 rucaparib or six placebo cycles on treatment. Treatment-related adverse events (all grades) of fatigue (63.2% v 30.0%), nausea (36.8% v 5.0%), rash (21.1% v 0%), and raised alanine aminotransferase (57.9% v 10%) were more common with rucaparib. Conclusion: Maintenance rucaparib, following platinum-based chemotherapy, extended PFS in DRD biomarker-selected patients with mUC and was tolerable. Further investigation of poly ADP-ribose polymerase inhibition in selected patients with mUC is warranted.Citation
Crabb SJ, Hussain S, Soulis E, Hinsley S, Dempsey L, Trevethan A, et al. A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022 Aug 12:JCO2200405. PubMed PMID: 35960902. Epub 2022/08/13. eng.Journal
Journal of Clinical OncologyDOI
10.1200/jco.22.00405PubMed ID
35960902Additional Links
https://dx.doi.org/10.1200/jco.22.00405Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/jco.22.00405